Most of the information found on this website comes from RSS Feeds. It is an automated task that provides the information to you. We try to limit items that are duplicates, but with many feeds this can be difficult. Since the owner of this website also has MS and is legally blind this service was necessary to keep the website running with as much automation as possible. Volunteers help from time to time but many have disabilities themselves. We thank you for visiting us and hope that MSC can be of service to you and your loved ones.
This site is designed to inform and support those with Multiple Sclerosis. It is not a comprehensive medical guide to the disease. This information is taken from many different resources. The writings on this site are not intended to diagnose nor treat. The ideas and writings seen here are not to be substituted for the medical advice of a practicing physician. Prayer is a wonderful treatment but when God does not heal someone it may be necessary for medical treatment of MS.
Novartis‘ Gilenya (fingolimod), Sanofi Genzyme‘s Aubagio (teriflunomide), and Biogen’s Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) are the top disease-modifying therapies to which patients with Multiple Sclerosis (MS) have most frequently switched in Europe recently. That’s according to a survey of more than 270 neurologists, conducted by Spherix Global Insights. Among people with Primary Progressive Multiple Sclerosis (PPMS), switches to […]
Interleukin-17A (IL-17A), a molecule that mediates immune and inflammatory responses, likely promotes inflammation and tissue damage in relapsing-remitting Multiple Sclerosis (RRMS) and should be considered a potential target for treating the disease, a study reports. The findings of the study, “IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting Multiple Sclerosis,” were […]
The post Immune System Molecule IL-17A Likely Inflammatory Agent in RRMS, Study Says appeared first on Multiple Sclerosis News Today.